Generated by AI
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 23's posts. Generated by AI.
Summary of Feb 14's posts. Generated by AI.
Summary of Apr 9's posts. Generated by AI.
Investors talking about PRQR also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.
ProQR Therapeutics N.V. Ordinary Shares represent ownership in ProQR Therapeutics N.V., a clinical-stage biotechnology company focused on RNA-based medicines. ProQR develops therapies built on its Axiomer RNA editing platform, which is designed to address genetic disorders with unmet medical needs. Its current work centers on discovering and developing novel therapeutic candidates for severe rare diseases, with particular attention to inherited conditions and other genetic targets. The company operates in the biotechnology and healthcare sectors, where RNA medicine is an important area of research because it aims to modify disease-related genetic messages rather than conventional protein targets. ProQR Therapeutics N.V. serves as a specialized participant in the broader life sciences market, supporting research, clinical development, and potential commercialization pathways for next-generation genetic therapies. Headquartered in Leiden, the Netherlands, the company also maintains a presence in Cambridge, Massachusetts.
WebsiteZernikedreef 9
Leiden, 2333 CK
Netherlands
The latest articles about PRQR.
ProQR to present its ADAR-mediated RNA editing approach and progress toward next-generation editing oligonucleotides at TIDES Europe plenary sessi...